期刊文献+

ICU产ESBLs大肠埃希菌氨基糖苷类修饰酶基因的分析 被引量:6

下载PDF
导出
摘要 大肠埃希菌是临床常见的条件致病菌,也是重症监护病房(ICU)感染的主要病原菌之一。近年来,随着抗生素的广泛使用,产超广谱β-内酰胺酶(ESBLs)大肠埃希菌日益增多。ESBLs由质粒介导,易在种属甚至不同种属细菌间传递造成暴发流行。这一现象已成为医院感染的突出问题。氨基糖苷类抗菌药物(aminoglycosides,
出处 《检验医学》 CAS 2013年第5期452-454,共3页 Laboratory Medicine
  • 相关文献

参考文献9

  • 1Gootz TD. The forgotten Gram-negative bacilli: what genetic determinants are telling us about the spread of antibiotic resistance [ J ]. Biochem Pharmaco1,2006,71 (7) : 1073-1084.
  • 2D'Azevedo PA, Goncalves AL, Musskopf MI, et al. Laboratory tests in the detection of extended spectrum beta-lactamase production: National Committee for Clinical Laboratory Standards(NCCI_S) screening test, the E-test, the double disk confirmatory test, and cefoxitin susceptibility testing [ J ]. Braz J Infect Dis, 2004,8(5) :372-377.
  • 3游春芳,黄永茂,张馨琢,邓敏,陈枫,钟利,陈庄.产ESBLs大肠埃希菌对氨基糖苷类抗菌药物的耐药性探讨[J].中华实验和临床感染病杂志(电子版),2010,4(3):14-17. 被引量:10
  • 4王辉,陈民钧,倪语星,陈冬梅,孙自庸,陈燕,赵旺胜,邹雄,俞云松,胡志东,黄心宏,徐英春,谢秀丽,褚云卓,王倩,梅亚宁,田彬,张蓓,孔庆莲,于秀娟,潘玉红.2003—2004年中国十家教学医院革兰阴性杆菌的耐药分析[J].中华检验医学杂志,2005,28(12):1295-1303. 被引量:236
  • 5黄永茂,游春芳,张馨琢,邓敏,陈枫,钟利,陈庄.产ESBLs大肠埃希菌氨基糖苷类抗菌药耐药性及修饰酶基因的研究[J].重庆医学,2010,39(15):1948-1950. 被引量:3
  • 6Van der Bijl P. Aminoglycoside monitoring: perspective on current trends in the Western Cape[J]. S Afr Med J, 2005,95(7) : 474-477.
  • 7罗建华.产超广谱β内酰胺酶大肠埃希菌中氨基糖苷类修饰酶基因分布研究[D].浙江:浙江大学,2011.
  • 8张卓然,夏梦岩,倪语星.微生物耐药的基础与临床[M].北京:人民卫生出版社,2006.396-398.
  • 9Karisik E, Ellington M J, Pike R, et al. Molecular characterization of plasmids encoding CTX-M-15 beta- lactamases from Escherichia coli strains in the United Kingdom [ J ]. J Antimicrob Chemother, 2006,58 ( 3 ) : 665 -668.

二级参考文献21

共引文献253

同被引文献59

  • 1李正龙.呼吸内科感染产ESBLS大肠埃希菌的临床分析[J].求医问药(下半月),2013(2):32-33. 被引量:2
  • 2许宏涛,张秀珍.医院感染铜绿假单胞菌多重耐药机制的研究[J].中国抗感染化疗杂志,2005,5(3):141-145. 被引量:58
  • 3Ren J,Lin W T, Shen Y J,et al.Optimization of fermentation media for ni- trite oxidizing bacteria usingsequential statistical design[J].Biores Technol 2008,99:7923-7927.
  • 4Jacoby GA. Medeiros AA. More extended - spectrum betaiactamases[J]. Antimircrob agents chemother, 1991,35:1697.
  • 5National Committee for Clinical Laboratory Standards,Performance standards for antimicrobial susceptibility testing [S].10th informational supplement(aerobic dilution).M100-S10. Wayne, Pa:NCCLS,2009.
  • 6Biswas T, Das M, Mondal R, et al. Prevalence of ESBL producing Escherichia Colt and Klebsiella species with their co-resistance pattern to antimicrobials [ J]. Mymensingh Med J, 2013,22(2) :377-384.
  • 7Ababneh M, Harpe S, Oinonen M, et al. Trends in aminoglycoside use and gentamicin-resistant gram-negative clinical isolates in US academic medical centers: impli- cations for antitnicrobial stewardship [ J]. Infect Control Hosp Epidemio1,2012,33 (6):594-601.
  • 8Fournier S, Brun-Buisson C, Jarlier V. Twenty years of antimicrobial resistance control programme in a regional multi hospital institution, with focus on emerging bacteria ( VRE and CPE ) [ J ]. Antimicrob Resist Infect Control,2012,1(1) :9.
  • 9Peripi SB, Thadepalli VG, Khagga M, et al. Profile of antibiotic consumption, sensitivity and resistance in an urban area of Andhra Pradesh, India [J]. Singapore Med J,2012,53 (4) :268-272.
  • 10Gupta N,Limbago BM,Patel JB,et al.Carbapenem-resistant Enterobacteriaceae:epidemiology and prevention[J].Clin Infect Dis,2011,53(1):60-7.

引证文献6

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部